## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b)

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Reilly Joseph H.							2. Issuer Name and Ticker or Trading Symbol  Minerva Neurosciences, Inc. [ NERV ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify				
(Last) (First) (Middle) C/O MINERVA NEUROSCIENCES, INC. 1601 TRAPELO ROAD, SUITE 286						3. Date of Earliest Transaction (Month/Day/Year) 10/01/2018								X Officer (give title Other (specify below)  SVP & Chief Operating Officer					
(Street) WALTHAM MA 02451					_   4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person				
(City)	(S	tate)			-														
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transact Date (Month/Day)						2 Ear) if	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securiti	es Acquirec Of (D) (Instr	l (A) or	5. Amo Securit Benefic	5. Amount of Securities Beneficially Owned Following		: Direct   c	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)	
Common Stock 10/01/2						018			M		15,000	A	\$4.7	1 29	9,177	D			
Common Stock 10/01/2									М		10,000	A	\$5.1	9 39	9,177		D		
Common Stock 10/01/2						3			S <sup>(1)</sup>		23,300	D	\$12.02	2(2) 1	5,877		D		
Common Stock 10/01/2						2018			S <sup>(1)</sup>		1,700	D	\$12.62	2(3) 14	,177		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	ed Date,	4. Transa Code ( 8)	ction	5. Number of		6. Date Exercis Expiration Dat (Month/Day/Ye		sable and	7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares						
Employee Stock Option (Right to Buy)	\$4.71	10/01/2018			M			15,000	(4)		12/03/2025	Common Stock	15,000	\$0.00	27,40	0	D		
Employee Stock Option (Right to	\$5.19	10/01/2018			M			10,000	(5)		04/13/2025	Common Stock	10,000	\$0.00	47,52	4	D		

#### **Explanation of Responses:**

- 1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2016.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$11.60 to \$12.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.60 to \$12.69, inclusive.
- 4. This option vested 25% on December 4, 2016 and then in quarterly installments over 3 years thereafter.
- 5. This option vested 25% on April 14, 2016 and then in quarterly installments over 3 years thereafter.

# Remarks:

/s/ Matt Bartholomae, 10/03/2018 Attorney-in-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.